Xiaoying Yin, MD

Assistant Professor

Specialty:

Cancer cachexia, tumor vaccines in head and neck cancer

Education:

• MD: Xi'an Medical University, Xi'an, China, 1983

• Residency: Pathology, Xi'an Medical University, Xi'an, China, 1983-1986

• Fellowship: Pathology, University of Pittsburgh, Pittsburgh, PA, 1988-1990

• MS: Molecular Biology, University of Pittsburgh, Pittsburgh, PA, 1993

Professional Experience:

• Assistant Professor, Department of Otolaryngology/Head and Neck Surgery, UNC, 2007-present
• Senior Research Associate, Lineberger Cancer  Center, University of North Carolina, 2002-2007
• Research Assistant Professor, Department of Hematology/Oncology, Children's Hospital of Pittsburgh, 2001-2002
• Research Laboratory Supervisor, Department of Hematology/Oncology, Children's Hospital of Pittsburgh,1996-2001
• Research Associate, Department of Hematology/Oncology, Children's Hospital of Pittsburgh,1993-1996
• Graduate Research Assistant, Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, 1991-1993
• Pathologist, Shannxi Cancer Institute, Xi'an, China, 1987-1988

Recent Publications:

• Couch ME, Jaffee E, Yin X, Cannon TY, Epperly C, Cowherd S, Kirby S, Moran T, Serody J. Allogenic genetically engineered tumor vaccine with immunomodulation for head and neck cancer. Arch Otolaryngol (submitted)
• Yin XY, Zhang H, Burrows F, Zhang L, Shores CG. The effect of EC78, a ovel Hsp90 inhibitor alone and in combination with radiation in head and neck squamous cell carcinoma. (in preparation)
• Yin XY, Shores CG. Identification of gene expression profile associated with cisplatin sensitivity in head and neck squamous cell carcinima cell lines. (in preparation)
• Couch ME, Jaffee E, Yin XY, Epperly C, Cowherd S, George J, Kirby S, Moran T, Serody J. Immunomodulation of an allogenic cytokine-secreting vaccine in head/neck model. (in preparation)
• Cannon T, Couch ME, Yin XY, Guttridge D, Lai V, Shores C. Comparison of animal models for head and neck cancer cachexia. Laryngoscope 2007 Oct; Epub ahead of print.
• Cannon T, Shores C, Yin XY, Dahlman DJ, Guttridge D, Lai V, George J, Buzkova P, Couch ME. Immunocompetent Murine Model of Cancer Cachexia for Head & Neck Squamous Cell Carcinoma. Head &Neck 2007 Jul, Epub ahead of print.
• Richey LM, George JR, Couch ME, Kanapkey BK, Yin X, Cannon T, Stewart PW, Weissler MC, Shores CG. Defining cancer cachexia in head and neck squamous cell carcinoma. Clin Cancer Res 2007 Nov;15;13(22 Pt 1):6561-7.
• Yin X, Zhang H, Burrows F, Zhang L, Shores C. Potent activity of a noval dimeric Hsp90 inhibitor against Head and Neck Squamous cell carcinoma in vitro and in vivo. Clinical Cancer Research 2005;11:3889-3896.
• Zanation AM, Yin XY, Shores C, Yarbrough WG. Phenotypic and microarray gene expression analysis of tri-dimensional raft-modeled human head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004;131(5):577-584.
• Chung CH, Parker JS, Funkhouser WK, Yin X, Shockley WW, Shores CG, Yarbrough WG, Perou CM. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5(5):489-500.
• Shores CG, Yin X, Funkhouser W, Yarbrough WG. Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(8):937-942.
• Yin X, Giap C, Lazo J, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003 Sep;18;22(40):6151-6159.
• Mu ZM, Yin X, Prochownik EV. Pag, a putitative tumor suppressor that interact with "Myc box II" domain of c-Myc and selectively alters its biological function and target gene expression. J. Bio.Chem 2002;277(45):43175-43184.
• Yin X, Grove L, Rogulski K, Prochownik EV. MT-MC1, a novel c-Myc target, that recapitulates multiple c-Myc phenotypes. J. Bio. Chem 2002;277(22):19998-20010.